Pautier, P., Locher, C., Robert, C., Deroussent, A., Flament, C., Le Cesne, A., . . . Paci, A. (2013). Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate. Landes Bioscience.
शिकागो स्टाइल उद्धरणPautier, Patricia, et al. Phase I Clinical Trial Combining Imatinib Mesylate and IL-2 in Refractory Cancer Patients: IL-2 Interferes With the Pharmacokinetics of Imatinib Mesylate. Landes Bioscience, 2013.
एमएलए उद्धरणPautier, Patricia, et al. Phase I Clinical Trial Combining Imatinib Mesylate and IL-2 in Refractory Cancer Patients: IL-2 Interferes With the Pharmacokinetics of Imatinib Mesylate. Landes Bioscience, 2013.
चेतावनी: ये उद्धरण हमेशा 100% सटीक नहीं हो सकते हैं.